CXCR1 and breast carcinoma: Importantly, pharmacological inhibitors of CXCR1/2 are already in clinical trials for several inflammatory diseases including COPD, asthma, and rheumatoid arthritis as well as for certain cancers including breast cancer and melanoma11,42.